دورية أكاديمية
The changing landscape of small cell lung cancer.
| العنوان: | The changing landscape of small cell lung cancer. |
|---|---|
| المؤلفون: | Cittolin-Santos GF; Division of Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA., Knapp B; Division of Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA., Ganesh B; Departments of Medicine and Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Gao F; Division of Public Health Science, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Missouri, USA., Waqar S; Division of Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA., Stinchcombe TE; Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, USA., Govindan R; Division of Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA., Morgensztern D; Division of Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA. |
| المصدر: | Cancer [Cancer] 2024 Mar 12. Date of Electronic Publication: 2024 Mar 12. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005- >: Hoboken, NJ : Wiley Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.] |
| مستخلص: | Background: Small-cell lung cancer (SCLC) is characterized by rapid proliferation and early dissemination. The objective of this study was to examine the demographic trends and outcomes in SCLC. Methods: The authors queried the National Cancer Institute's Surveillance, Epidemiology, and End Results database to assess the trends in incidence, demographics, staging, and survival for SCLC from 1975 to 2019. Trends were determined using joinpoint analysis according to the year of diagnosis. Results: Among the 530,198 patients with lung cancer, there were 73,362 (13.8%) with SCLC. The incidence per 100,000 population peaked at 15.3 in 1986 followed by a decline to 6.5 in 2019. The percentage of SCLC among all lung tumors increased from 13.3% in 1975 to a peak of 17.5% in 1986, declining to 11.1% by 2019. There was an increased median age at diagnosis from 63 to 69 years and an increased percentage of women from 31.4% to 51.2%. The percentage of stage IV increased from 58.6% in 1988 to 70.8% in 2010, without further increase. The most common sites of metastasis at diagnosis were mediastinal lymph nodes (75.3%) liver (31.6%), bone (23.7%), and brain (16.4%). The 1-year and 5-year overall survival rate increased from 23% and 3.6%, respectively, in 1975-1979 to 30.8% and 6.8%, respectively, in 2010-2019. Conclusions: The incidence of SCLC peaked in 1988 followed by a gradual decline. Other notable changes include increased median age at diagnosis, the percentage of women, and the percentage of stage IV at diagnosis. The improvement in 5-year overall survival has been statistically significant but clinically modest. (© 2024 American Cancer Society.) |
| References: | Ganti AKP, Loo BW, Bassetti M, et al. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2021;19(12):1441-1464. doi:10.6004/jnccn.2021.0058. Wang Q, Gumus ZH, Colarossi C, et al. SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J Thorac Oncol. 2023;18(1):31-46. doi:10.1016/j.jtho.2022.10.002. Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37(4):278-285. doi:10.1200/jco.18.01585. Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116-1125. doi:10.1016/s1470-2045(17)30318-2. Bogart J, Wang X, Masters G, et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023;41(13):2394-2402. doi:10.1200/jco.22.01359. Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220-2229. doi:10.1056/nejmoa1809064. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939. doi:10.1016/s0140-6736(19)32222-6. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol. 2006;24(28):4539-4544. doi:10.1200/jco.2005.04.4859. Cummings KM, Proctor RN. The changing public image of smoking in the United States: 1964-2014. Cancer Epidemiol Biomarkers Prev. 2014;23(1):32-36. doi:10.1158/1055-9965.epi-13-0798. Cornelius ME, Loretan CG, Jamal A, et al. Tobacco product use among adults-United States, 2021. MMWR Morb Mortal Wkly Rep. 2023;72(18):475-483. doi:10.15585/mmwr.mm7218a1. Garfinkel L. Trends in cigarette smoking in the United States. Prev Med. 1997;26(4):447-450. doi:10.1006/pmed.1997.0191. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763. Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst. 1999;91(8):675-690. doi:10.1093/jnci/91.8.675. Jemal A, Miller KD, Ma J, et al. Higher lung cancer incidence in young women than young men in the United States. N Engl J Med. 2018;378(21):1999-2009. doi:10.1056/nejmoa1715907. Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology. 1992;3(1):61-64. doi:10.1097/00001648-199201000-00012. Schoenberg JB, Wilcox HB, Mason TJ, Bill J, Stemhagen A. Variation in smoking-related lung cancer risk among New Jersey women. Am J Epidemiol. 1989;130(4):688-695. doi:10.1093/oxfordjournals.aje.a115390. Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer. 1993;54(1):44-48. doi:10.1002/ijc.2910540108. Dumoulin DW, Aarts MJ, De Ruysscher D, Aerts J, Dingemans AC. Trends in the epidemiology of small-cell lung cancer: a Dutch nationwide population-based study over 1989-2020. Eur J Cancer. 2023;191:112985. doi:10.1016/j.ejca.2023.112985. Xanthopoulos EP, Corradetti MN, Mitra N, et al. Impact of PET staging in limited-stage small-cell lung cancer. J Thorac Oncol. 2013;8(7):899-905. doi:10.1097/jto.0b013e31828e8996. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e400S-e419S. doi:10.1378/chest.12-2363. Lee JW, Lee SM, Lee HS, Kim YH, Bae WK. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer. Ann Nucl Med. 2012;26(8):627-633. doi:10.1007/s12149-012-0622-3. Hochstenbag MM, Twijnstra A, Wilmink JT, Wouters EF, ten Velde GP. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol. 2000;48(3):243-248. doi:10.1023/a:1006427407281. Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer. 2008;112(8):1827-1834. doi:10.1002/cncr.23361. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706-714. doi:10.1097/jto.0b013e31812f3c1a. Shojaee S, Singh I, Solsky I, Nana-Sinkam P. Malignant pleural effusion at presentation in patients with small-cell lung cancer. Respiration. 2019;98(3):198-202. doi:10.1159/000499372. National Lung Screening Trial Research Team; Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/nejmoa1102873. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330-338. doi:10.7326/m13-2771. Thomas A, Pattanayak P, Szabo E, Pinsky P. Characteristics and outcomes of small cell lung cancer detected by CT screening. Chest. 2018;154(6):1284-1290. doi:10.1016/j.chest.2018.07.029. Singareddy A, Flanagan ME, Samson PP, et al. Trends in stage I lung cancer. Clin Lung Cancer. 2023;24(2):114-119. doi:10.1016/j.cllc.2022.11.005. Wang X, Wang Z, Pan J, et al. Patterns of extrathoracic metastases in different histological types of lung cancer. Front Oncol. 2020;10:715. doi:10.3389/fonc.2020.00715. Megyesfalvi Z, Tallosy B, Pipek O, et al. The landscape of small cell lung cancer metastases: organ specificity and timing. Thorac Cancer. 2021;12(6):914-923. doi:10.1111/1759-7714.13854. Wang S, Tang J, Sun T, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep. 2017;7(1):1339. doi:10.1038/s41598-017-01571-0. Bogart JA, Waqar SN, Mix MD. Radiation and systemic therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2022;40(6):661-670. doi:10.1200/jco.21.01639. Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265-271. doi:10.1056/nejm199901283400403. Zugazagoitia J, Paz-Ares L. Extensive-stage small-cell lung cancer: first-line and second-line treatment options. J Clin Oncol. 2022;40(6):671-680. doi:10.1200/jco.21.01881. Mathieu L, Shah S, Pai-Scherf L, et al. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. Oncologist. 2021;26(5):433-438. doi:10.1002/onco.13752. |
| فهرسة مساهمة: | Keywords: Surveillance, Epidemiology, and End Results (SEER); incidence; joinpoint analysis; overall survival; small cell lung cancer; smoking; tobacco |
| تواريخ الأحداث: | Date Created: 20240312 Latest Revision: 20240312 |
| رمز التحديث: | 20240312 |
| DOI: | 10.1002/cncr.35281 |
| PMID: | 38470453 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.35281 |